{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:48:42Z","timestamp":1785754122531,"version":"3.56.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oritavancin, a long-acting lipoglycopeptide antibiotic, demonstrates bactericidal activity against gram-positive pathogens including drug-resistant strains. Despite its established efficacy and pharmacokinetic advantages, post-marketing safety data remain limited. The growing off-label use of oritavancin for complex infections further underscores the urgent need for large-scale safety evaluation. To address this gap, we conducted a comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database to characterize the real-world adverse event profile of oritavancin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed all adverse event reports that identified oritavancin as the primary suspected drug since 2014 in the FAERS database. Using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) algorithms, we conducted a comprehensive analysis of oritavancin-related AEs, restricting the analysis to AEs with the role code of primary suspect (PS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16, 964, 725 reports were extracted from the FAERS database, among which 1, 088 listed oritavancin as the \u201cprimary suspected\u201d drug. We identified seven significant signals at the system organ class (SOC) level and 48 at the preferred term (PT) level. We confirmed multiple established labeled adverse events with strong reporting signals, including chills (n = 156, ROR\u00a0=\u00a027.84). Notably, multiple signals not documented in the product label emerged, sorted by descending case count: dyspnoea (n = 98, ROR\u00a0=\u00a03.41), chest discomfort (n = 29, ROR\u00a0=\u00a05.64), anaphylactic reaction (n = 25, ROR\u00a0=\u00a09.07), hyperhidrosis (n = 24, ROR\u00a0=\u00a03.80), neck pain (n = 14, ROR\u00a0=\u00a04.85), hypoxia (n = 9, ROR\u00a0=\u00a05.21), throat tightness (n = 7, ROR\u00a0=\u00a05.40), flank pain (n = 5, ROR\u00a0=\u00a011.03), tachypnoea (n = 5, ROR\u00a0=\u00a07.46), groin pain (n = 4, ROR\u00a0=\u00a08.80), respiratory depression (n = 4, ROR\u00a0=\u00a06.80). Distinct signal patterns were also observed across sex and age subgroups and should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world pharmacovigilance analysis corroborates the known labeled safety profile of oritavancin and identifies multiple underemphasized signals not fully specified in the product label, involving the neurological, respiratory, cardiovascular, and musculoskeletal systems. These disproportionality signals from spontaneous reporting reflect only statistical associations rather than definitive causality, and warrant further verification to inform clinical safety monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1798934","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:23:11Z","timestamp":1785752591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oritavancin safety: a real-world pharmacovigilance study of the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Cardiology, Chengdu Integrated TCM & Western Medicine Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chengdu Integrated TCM & Western Medicine Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Chi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jiao","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1056\/NEJMp2031891","article-title":"Vancomycin infusion reaction - moving beyond \u201cred man syndrome","volume":"384","author":"Alvarez-Arango","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101498","article-title":"The clinical efficacy of multidose oritavancin: a systematic review","volume":"12","author":"Baiardi","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01873-17","article-title":"Evaluation of oritavancin dosing strategies against vancomycin-resistant enterococcus faecium isolates with or without reduced susceptibility to daptomycin in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"62","author":"Belley","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaip.2017.05.005","article-title":"The role of the clinical history in drug allergy prediction","volume":"6","author":"Blumenthal","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01667-21","article-title":"Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010-2019)","volume":"66","author":"Carvalhaes","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-200831020-00002","article-title":"Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management","volume":"31","author":"Cheshire","year":"2008","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc Am."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01919-17","article-title":"Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: summary of safety analysis from the phase 3 SOLO studies","volume":"62","author":"Corey","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/ACI.0000000000000665","article-title":"Adverse reactions to vancomycin and cross-reactivity with other antibiotics","volume":"20","author":"De Luca","year":"2020","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2026-005052","article-title":"Putting FAERS data into perspective: cautionary considerations for comparative safety assessment","author":"Gkrinia","year":"2026","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.11641","article-title":"Comparative effectiveness of long-acting lipoglycopeptides vs standard-of-care antibiotics in serious bacterial infections","volume":"8","author":"Goodman-Meza","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac090","article-title":"Kimyrsa, an oritavancin-containing product: clinical study and review of properties","volume":"9","author":"Hoover","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/DDDT.S324285","article-title":"Kimyrsa and orbactiv - a tale of two formulations","volume":"17","author":"Jackson","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","article-title":"Drug allergy","volume":"125","author":"Khan","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1097\/CORR.0000000000003449","article-title":"Can oritavancin be used for treatment and\/or suppressive antimicrobial therapy of bone and joint infections caused by vancomycin-resistant enterococcus faecium","volume":"483","author":"Krsak","year":"2025","journal-title":"Clin. Orthop."},{"key":"B21","unstructured":"Labeling Information"},{"key":"B22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jaip.2017.02.014","article-title":"Practical management of antibiotic hypersensitivity in 2017","volume":"5","author":"Macy","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against staphylococcus aureus, enterococcus faecalis and enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/jac\/dkw319","article-title":"Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency","volume":"71","author":"Mendes","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1128\/AAC.02482-13","article-title":"Oritavancin activity against staphylococcus aureus causing invasive infections in U.S. and european hospitals: a 5-year international surveillance program","volume":"58","author":"Mendes","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of gram-positive infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B30","first-page":"1781","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am. Fam. Physician"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248129","article-title":"Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital","volume":"16","author":"Saddler","year":"2021","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2025-9-4","article-title":"Evaluating oritavancin for gram-positive infections: a systematic review of on-label and off-label use","volume":"15","author":"Soriano","year":"2026","journal-title":"Drugs Context"},{"key":"B35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106069","article-title":"Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review","volume":"56","author":"Thomas","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02614-20","article-title":"New perspectives on antimicrobial agents: long-acting lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs - Real World Outcomes"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1798934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:23:15Z","timestamp":1785752595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1798934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":40,"alternative-id":["10.3389\/fcimb.2026.1798934"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1798934","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1798934"}}